Loading...
•
Sep 30, 2025
Genmab Q3 2025 Earnings Report
Genmab reported Q3 2025 results with strong year-over-year revenue and profitability growth.
Key Takeaways
For the three months ended September 30, 2025, Genmab generated $1022000000 in revenue and reported net income of $401000000. Diluted EPS was $6.46 and Earnings per ADS were $0.65.
Revenue was $1022000000 for the quarter.
Net income was $401000000.
Diluted EPS was $6.46.
Earnings per ADS were $0.65.
Forward Guidance
Genmab reaffirmed its 2025 financial guidance supported by strong revenue growth and pipeline progress.
Positive Outlook
- Revenue exceeded $1.02 billion.
- Net income reached $401000000.
- Positive Earnings per ADS of $0.65.
- Strong royalty and product revenue growth.
- Continued pipeline advancement.
Challenges Ahead
- Regulatory approval risks remain.
- Dependence on key partnered products.
- Clinical development risks.
- Competitive landscape pressures.
- Potential FX volatility impact.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...